Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

LESSONS LEARNED. Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status. Whether this combination is superior to tem...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes‐Botero, Germán, Cartalat‐Carel, Stéphanie, Chinot, Olivier L., Barrie, Maryline, Taillandier, Luc, Beauchesne, Patrick, Catry‐Thomas, Isabelle, Barrière, Jérôme, Guillamo, Jean‐Sebastien, Fabbro, Michel, Frappaz, Didier, Benouaich‐Amiel, Alexandra, Le Rhun, Emilie, Campello, Chantal, Tennevet, Isabelle, Ghiringhelli, François, Tanguy, Marie‐Laure, Mokhtari, Karima, Honnorat, Jérôme, Delattre, Jean‐Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947454/
https://www.ncbi.nlm.nih.gov/pubmed/29472310
http://dx.doi.org/10.1634/theoncologist.2017-0689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947454/
https://www.ncbi.nlm.nih.gov/pubmed/29472310
http://dx.doi.org/10.1634/theoncologist.2017-0689

Ejemplares similares